|
TPM3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.22259999977426E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.84189999994511E-07 |
| Normal-vs-Stage2 |
9.437600E-01 |
| Normal-vs-Stage3 |
2.03479999999479E-05 |
| Normal-vs-Stage4 |
1.863210E-03 |
| Stage1-vs-Stage2 |
7.151100E-04 |
| Stage1-vs-Stage3 |
3.460400E-01 |
| Stage1-vs-Stage4 |
8.095000E-01 |
| Stage2-vs-Stage3 |
1.879830E-03 |
| Stage2-vs-Stage4 |
9.620900E-03 |
| Stage3-vs-Stage4 |
6.536200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.03490000019835E-07 |
| Normal-vs-AfricanAmerican |
7.79480000000499E-05 |
| Normal-vs-Asian |
4.970600E-04 |
| Caucasian-vs-AfricanAmerican |
4.535600E-01 |
| Caucasian-vs-Asian |
8.528800E-01 |
| AfricanAmerican-vs-Asian |
5.694800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.99550000000004E-05 |
| Normal-vs-Female |
2.0216999999656E-06 |
| Male-vs-Female |
9.195200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.09120000047325E-07 |
| Normal-vs-Age(41-60Yrs) |
1.363160E-04 |
| Normal-vs-Age(61-80Yrs) |
1.301980E-02 |
| Normal-vs-Age(81-100Yrs) |
1.118050E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.112190E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.739770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.327600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.691000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.509000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.364800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.932600E-01 |
| Classical-VS-Follicular |
4.44089209850063E-16 |
| Classical-VS-Other |
4.784000E-02 |
| Classical-VS-Normal |
7.87140352898064E-11 |
| Tall-VS-Follicular |
1.57000000000629E-07 |
| Tall-VS-Other |
5.013700E-02 |
| Tall-VS-Normal |
9.72649999999575E-05 |
| Follicular-VS-Other |
4.329000E-01 |
| Follicular-VS-Normal |
7.504500E-02 |
| Other-VS-Normal |
9.220000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.218100E-02 |
| Normal-vs-N1 |
8.763000E-03 |
| N0-vs-N1 |
1.385760E-01 |
|
|
